ATXS
Price
$11.14
Change
+$0.02 (+0.18%)
Updated
Sep 27 closing price
40 days until earnings call
SNDX
Price
$18.89
Change
+$0.73 (+4.02%)
Updated
Sep 27 closing price
39 days until earnings call
Ad is loading...

ATXS vs SNDX

Header iconATXS vs SNDX Comparison
Open Charts ATXS vs SNDXBanner chart's image
Astria Therapeutics
Price$11.14
Change+$0.02 (+0.18%)
Volume$347.14K
CapitalizationN/A
Syndax Pharmaceuticals
Price$18.89
Change+$0.73 (+4.02%)
Volume$1.84M
CapitalizationN/A
View a ticker or compare two or three
ATXS vs SNDX Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ATXS vs. SNDX commentary
Sep 29, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and SNDX is a Hold.

COMPARISON
Comparison
Sep 29, 2024
Stock price -- (ATXS: $11.46 vs. SNDX: $20.54)
Brand notoriety: ATXS and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 101% vs. SNDX: 79%
Market capitalization -- ATXS: $628.58M vs. SNDX: $1.61B
ATXS [@Biotechnology] is valued at $628.58M. SNDX’s [@Biotechnology] market capitalization is $1.61B. The market cap for tickers in the [@Biotechnology] industry ranges from $531.37B to $0. The average market capitalization across the [@Biotechnology] industry is $3.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, SNDX is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 7 TA indicator(s) are bullish while SNDX’s TA Score has 5 bullish TA indicator(s).

  • ATXS’s TA Score: 7 bullish, 2 bearish.
  • SNDX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than SNDX.

Price Growth

ATXS (@Biotechnology) experienced а -5.60% price change this week, while SNDX (@Biotechnology) price change was -1.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.80%. For the same industry, the average monthly price growth was +5.34%, and the average quarterly price growth was -8.06%.

Reported Earning Dates

ATXS is expected to report earnings on Nov 07, 2024.

SNDX is expected to report earnings on Nov 06, 2024.

Industries' Descriptions

@Biotechnology (+3.80% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNDX($1.61B) has a higher market cap than ATXS($629M). ATXS YTD gains are higher at: 49.219 vs. SNDX (-4.951).
ATXSSNDXATXS / SNDX
Capitalization629M1.61B39%
EBITDAN/AN/A-
Gain YTD49.219-4.951-994%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total Cash18.6MN/A-
Total Debt168KN/A-
FUNDAMENTALS RATINGS
ATXS vs SNDX: Fundamental Ratings
ATXS
SNDX
OUTLOOK RATING
1..100
1661
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
87
Overvalued
PROFIT vs RISK RATING
1..100
10044
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
4861
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (64) in the Biotechnology industry is in the same range as SNDX (87). This means that ATXS’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's Profit vs Risk Rating (44) in the Biotechnology industry is somewhat better than the same rating for ATXS (100). This means that SNDX’s stock grew somewhat faster than ATXS’s over the last 12 months.

SNDX's SMR Rating (96) in the Biotechnology industry is in the same range as ATXS (97). This means that SNDX’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's Price Growth Rating (48) in the Biotechnology industry is in the same range as SNDX (61). This means that ATXS’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for ATXS (100). This means that SNDX’s stock grew significantly faster than ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSSNDX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend about 1 month ago
0%
Bullish Trend about 1 month ago
0%
Momentum
ODDS (%)
Bullish Trend about 1 month ago
0%
Bullish Trend about 1 month ago
0%
MACD
ODDS (%)
Bullish Trend about 1 month ago
0%
Bearish Trend about 1 month ago
0%
TrendWeek
ODDS (%)
Bullish Trend about 1 month ago
0%
Bullish Trend about 1 month ago
0%
TrendMonth
ODDS (%)
Bullish Trend about 1 month ago
0%
Bearish Trend about 1 month ago
0%
Advances
ODDS (%)
Bullish Trend about 1 month ago
0%
Bullish Trend about 2 months ago
83%
Declines
ODDS (%)
Bearish Trend about 2 months ago
0%
Bearish Trend about 2 months ago
0%
BollingerBands
ODDS (%)
Bullish Trend about 1 month ago
0%
Bullish Trend about 1 month ago
0%
Aroon
ODDS (%)
Bullish Trend about 1 month ago
0%
Bullish Trend about 1 month ago
0%
View a ticker or compare two or three
Ad is loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME23.14-0.28
-1.20%
GameStop Corp
TSLA210.60-3.51
-1.64%
Tesla
SPY552.08-11.60
-2.06%
SPDR® S&P 500® ETF Trust
AAPL222.77-6.23
-2.72%
Apple
BTC.X57431.023000-1681.457000
-2.84%
Bitcoin cryptocurrency

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with KALV. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then KALV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
-6.30%
KALV - ATXS
41%
Loosely correlated
-7.62%
ADCT - ATXS
38%
Loosely correlated
-5.86%
FULC - ATXS
37%
Loosely correlated
-5.26%
SNDX - ATXS
37%
Loosely correlated
-0.05%
INZY - ATXS
36%
Loosely correlated
-5.60%
More

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with RLAY. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then RLAY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
-0.05%
RLAY - SNDX
49%
Loosely correlated
-4.71%
BBIO - SNDX
46%
Loosely correlated
+3.20%
NTLA - SNDX
46%
Loosely correlated
-3.65%
RNA - SNDX
46%
Loosely correlated
-6.84%
BPMC - SNDX
45%
Loosely correlated
-3.15%
More